Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-07-01-Speech-2-151"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-07-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Strengthening the European pharmaceutical industry in the interest of patients – proposals for action2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20030701.6.2-151"2
lpv:hasSubsequent	lp_eu:2003-07-01-Speech-2-1522
lpv:speaker	lp:Didier Rod2
lpv:spokenAs	substitute; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3 vice-president; Members from the European Parliament to the Joint Parliamentary Assembly of the Agreement between the African, Caribbean and Pacific States and the European Union (ACP-EU) (2003-03-01--2004-07-19)3 unknown; Les Verts-Europe-Ecologie (1999-07-20--2004-07-19)3 member; G/EFA (1999-07-20--2004-07-19)3 member; Committee on Development and Cooperation (2002-01-17--2004-07-19)3
lpv:translated text	"Mr President, I must admit that I am pleased to hear Mr Byrne side with consumers against the pharmaceutical industry. We had the feeling, when addressing the pharmaceutical industry dossier and pharmaceutical legislation at the same time, that it was actually the European Parliament that was defending consumers, through far-reaching amendments, in particular on marketing authorisations, on centralised procedure and on consumer protection. The Commission’s answers to these questions, let us remember, were not what the European Parliament had hoped to hear. Fortunately, I have the impression today that the Council has reintroduced a number of items, such as the five-year renewal, marketing authorisations, the centralised procedure and stopping direct advertising to patients. All of this leads me to ask you whether your communication will accept a good number of the amendments to pharmaceutical legislation that Parliament has adopted by a large majority, particularly in the fields of direct advertising, consumer participation in the EMEA, centralised procedure and modifying marketing authorisation dossiers, as real proof of your concern to protect consumers and patients?"@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph